Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study of Fludarabine and Cyclophosphamide Plus MabThera Followed by Maintenance With MabThera on Failure-free Survival in Treatment-naïve Patients With Advanced Indolent B-cell Nonfollicular Lymphoma

NCT01153971 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01153971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01153971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study of Fludarabine and Cyclophosphamide Plus MabThera Followed by Maintenance With MabThera on Failure-free Survival in Treatment-naïve Patients With Advanced Indolent B-cell Nonfollicular Lymphoma
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
July 20, 2005
Completion date
September 24, 2010
Enrollment
47 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma